Teva Pharmaceutical Industries Price to Free Cash Flow Ratio 2010-2024 | TEVA

Teva Pharmaceutical Industries current price to free cash flow ratio as of January 24, 2025 is 17.41.

  • Teva Pharmaceutical Industries average price to free cash flow ratio for 2024 was 19.11, a 68.82% decline from 2023.
  • Teva Pharmaceutical Industries average price to free cash flow ratio for 2023 was 11.32, a 12.52% increase from 2022.
  • Teva Pharmaceutical Industries average price to free cash flow ratio for 2022 was 12.94, a 77.8% decline from 2021.

Price to free cash flow ratio can be defined as

Teva Pharmaceutical Industries Price to Free Cash Flow Ratio 2010-2024 | TEVA

  • Teva Pharmaceutical Industries average price to free cash flow ratio for 2024 was 19.11, a 68.82% decline from 2023.
  • Teva Pharmaceutical Industries average price to free cash flow ratio for 2023 was 11.32, a 12.52% increase from 2022.
  • Teva Pharmaceutical Industries average price to free cash flow ratio for 2022 was 12.94, a 77.8% decline from 2021.

Price to free cash flow ratio can be defined as

Related Stocks
Company NameMarket
Cap
Dr Reddy's Laboratories (RDY)$12.6B
BridgeBio Pharma (BBIO)$6.8B
Bausch Health Cos (BHC)$2.8B
Supernus Pharmaceuticals (SUPN)$2.1B
Amphastar Pharmaceuticals (AMPH)$1.7B
Personalis (PSNL)$396M
Taysha Gene Therapies (TSHA)$314M
Assembly Biosciences (ASMB)$95M
Sol-Gel Technologies (SLGL)$25M
Evoke Pharma (EVOK)$6M
Teligent (TLGT)$0M